John Ravits, MD
Affiliations: | Neurology | University of California, San Diego, La Jolla, CA |
Area:
Amyotrophic Lateral sclerosisGoogle:
"John Ravits"Mean distance: 106866
Children
Sign in to add trainee| Hugo Jae Mun Kim | research assistant | 2007-2009 | Benaroya Research Institute |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tazelaar GHP, Hop PJ, Seelen M, et al. (2022) Whole genome sequencing analysis reveals post-zygotic mutation variability in monozygotic twins discordant for amyotrophic lateral sclerosis. Neurobiology of Aging. 122: 76-87 |
| Krach F, Wheeler EC, Regensburger M, et al. (2022) Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis. Acta Neuropathologica |
| Gilley J, Jackson O, Pipis M, et al. (2021) Enrichment of alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders. Elife. 10 |
| Diaz-Garcia S, Ko VI, Vazquez-Sanchez S, et al. (2021) Nuclear depletion of RNA-binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathologica |
| Johnson JO, Chia R, Miller DE, et al. (2021) Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. Jama Neurology |
| Aladesuyi Arogundade O, Nguyen S, Leung R, et al. (2021) Nucleolar stress in C9orf72 and sporadic ALS spinal motor neurons precedes TDP-43 mislocalization. Acta Neuropathologica Communications. 9: 26 |
| Ho R, Workman MJ, Mathkar P, et al. (2020) Cross-Comparison of Human iPSC Motor Neuron Models of Familial and Sporadic ALS Reveals Early and Convergent Transcriptomic Disease Signatures. Cell Systems |
| Hor JH, Santosa MM, Lim VJW, et al. (2020) ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation. Cell Death and Differentiation |
| Miller T, Cudkowicz M, Shaw PJ, et al. (2020) Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS. The New England Journal of Medicine. 383: 109-119 |
| Brizzi KT, Bridges JFP, Yersak J, et al. (2020) Understanding the needs of people with ALS: a national survey of patients and caregivers. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-9 |